



## UPDATE IN HEMATOLOGY & ONCOLOGY October 7, 2023

Shanty Creek Resort | Bellaire, MI



### TARGET AUDIENCE

This continuing medical education program will be of interest to medical oncologists, hematologists, radiation oncologists, oncology nurses, advanced practice providers, as well as other healthcare professionals who deliver care to cancer patients.

### PROGRAM GOAL

MSHO's goal is to provide our learners with continuing education that is evidence-based and up to date. It will provide best practice guidelines and review recent peer-reviewed published data, free from commercial bias, to facilitate learner's development and implementation of standards of care as well as to close gaps in their professional practice.

## REGISTRATION DEADLINE SEPTEMBER 25, 2023

### REGISTRATION

This meeting is funded by the Michigan Society of Hematology and Oncology Foundation. There is no fee for MSHO members to attend as long as registration is received by September 25. [CLICK HERE](#) to register.

For more information, please contact MSHO at [meetings@msho.org](mailto:meetings@msho.org) or 248-385-5464.

### LODGING

Contact Shanty Creek directly at 866-695-5010 to check on availability and room rates. Other options to consider: VRBO, Airbnb, Traverse City, Boyne Mountain, Torch Lake, Gaylord. All of these areas are less than an hour away.

### DISCLOSURE STATEMENT

In accordance with the ACCME and Michigan State Medical Society Standards of Commercial Support, Munson Medical Center will implement mechanisms, prior to the planning and implementation of this CME activity, to identify and resolve conflicts of interest for all individuals in a position to control the content of this CME activity.

Applicable individual faculty and planning committee disclosures will be made prior to each presentation and provided in written material.

### ACCREDITATION AND CREDIT DESIGNATION STATEMENT

This activity has been planned and implemented in accordance with the Accreditation Elements and Policies of the Michigan State Medical Society through the joint sponsorship of Munson Healthcare and the Michigan Society of Hematology and Oncology. Munson Healthcare is accredited by the Michigan State Medical Society to provide continuing medical education for physicians.

Munson Healthcare designates this live activity for a maximum of *4.25 AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### LOCATION

Shanty Creek Resort  
5780 Shanty Creek Road  
Bellaire, MI 49615  
[www.shantycreek.com](http://www.shantycreek.com)

## PROGRAM DETAILS

### PROGRAM OBJECTIVES

At the conclusion of the activity, each learner will be able to:

- 1 Understand how tumor biomarker testing can influence treatment decisions and optimize clinical outcomes in hormone receptor positive, HER2-negative or low metastatic breast cancer.
- 1 Understand the current approach to metastatic renal cell carcinoma.
- 1 Identify patients who may benefit from radiation therapy to sites of oligometastatic cancer.
- 1 Review the latest data regarding the use of anti-CD38 antibodies and high-dose therapy with stem cell transplantation in patients with newly diagnosed multiple myeloma, and discuss the prospects of newer BCMA-directed therapies being incorporated into first-line therapy.

### PLANNING COMMITTEE

#### Daniel Isaac, DO

Course Director  
Michigan State University, Breslin Cancer Center

#### Jerome Winegarden, MD

MSHO President  
IHA Hematology and Oncology Consultants

#### Zachary Hector-Word, MD

MSHO Education Committee Member  
Cowell Family Cancer Center

#### Katie West, MSN, RN

CME Specialist  
Munson Healthcare

#### Mary Kay Makarewicz

Executive Director  
Michigan Society of Hematology & Oncology

## AGENDA

|          |   |
|----------|---|
| 6:30 am  | <b>BREAKFAST/REGISTRATION</b>   |
| 7:15 am  | <b>Opening Comments</b><br>Daniel Isaac, DO<br><i>Michigan State University</i>   |
| 7:30 am  | <b>Sequencing Endocrine and Chemotherapy in Metastatic, Hormone-Receptor Positive Breast Cancer</b><br>Erin Cobain, MD<br><i>University of Michigan</i> |
| 8:25 am  | <b>Selection of First Line Therapy For Newly Diagnosed Advanced Renal Cell Carcinoma</b><br>Yousef Zakharia, MD<br><i>The University of Iowa</i>        |
| 9:20 am  | <b>Fellow Poster Presentations</b>  |
| 9:40 am  | <b>BREAK</b>  |
| 10:00 am | <b>Radiation Therapy for Oligometastatic Cancer: Current State and Clinical Applications</b><br>William Jackson, MD<br><i>University of Michigan</i>    |
| 10:55 am | <b>Newly Diagnosed Multiple Myeloma: Controversies and Current Treatment Landscape</b><br>Jeffery Zonder, MD<br><i>Karmanos Cancer Institute</i>        |
| 12:00 pm | <b>COURSE ADJOURNS</b>  |

## FACULTY MEMBERS

#### Erin Cobain, MD

Assistant Professor  
Co-Director, Breast Cancer Clinical Research Team  
Division of Hematology/Oncology  
*University of Michigan Rogel Cancer Center*

#### Yousef Zakharia, MD

Associate Professor of Medicine  
Division of Oncology, Hematology and Blood & Marrow Transplantation  
Director Phase I Program  
Co-Leader GU Oncology Program  
*The University of Iowa and Holden Comprehensive Cancer Center*

#### William Jackson, MD

Assistant Professor  
Associate Residency Program Director  
Co-Chair, Genitourinary Oncology Clinical Research Team  
*University of Michigan*

#### Jeffrey Zonder, MD

Professor of Oncology  
Leader, Multiple Myeloma and Amyloidosis Multidisciplinary Team  
Co-Leader, Molecular Therapeutics  
*Barbara Ann Karmanos Cancer Institute*  
*Wayne State University*